AFF3 upregulation mediates tamoxifen resistance in breast cancers.

ABSTRACT:

Background

Although tamoxifen is a highly effective drug for treating estrogen receptor-positive (ER⁺) breast cancer, nearly all patients with metastasis with initially responsive tumors eventually relapse, and die from acquired drug resistance. Unfortunately, few molecular mediators of tamoxifen resistance have been described. Here, we describe AFF3 (AF4/FMR2 family member 3), which encodes a nuclear protein with transactivation potential that confers tamoxifen resistance and enables estrogen-independent growth.

Methods

We investigated AFF3 expression in breast cancer cells and in clinical breast cancer specimens with western blot and Real-time PCR. We also examined the effects of AFF3 knockdown and overexpression on breast cancer cells using luciferase, tetrazol

SUBMITTER: Shi Y 

PROVIDER: S-EPMC6192118 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature